Despite major advances in guideline-directed medical therapy (GDMT), worsening heart failure continues to drive significant morbidity, repeat hospitalizations and healthcare utilization worldwide. Identifying when a patient is transitioning from stable chronic heart failure to progressive disease remains one of the most important — and challenging — clinical decisions facing physicians today.

For Sheng Fu, M.D., advanced heart failure and transplant cardiologist at Baptist Health Miami Cardiac & Vascular Institute, one of the key issues is that patients can remain clinically stable for years before suddenly deteriorating.

“Patients with heart failure can do very well for a long period of time,” Dr. Fu says. “But once they begin to decline, that progression can happen very quickly.”

When Stable Heart Failure Becomes Worsening Heart Failure

In a recent segment for the Heart & Vascular Lecture Series by Baptist Health International, Dr. Fu notes that worsening heart failure often emerges gradually before accelerating clinically.

A common scenario involves a patient with reduced ejection fraction who initially responds well to therapy, experiences years of relative stability — and then begins developing recurrent symptoms, medication intolerance or repeat hospitalizations.

“Sometimes both the patient and the clinician are caught off guard,” Dr. Fu says. “A patient who has been stable for years suddenly has multiple hospitalizations within months.”

The transition from chronic heart failure to worsening heart failure is clinically significant because recurrent decompensation is associated with markedly worse outcomes.

Clinical indicators that may signal progression include:

• Recurrent heart failure hospitalizations or emergency department visits
• Escalating diuretic requirements
• Persistent congestion despite therapy optimization
• Declining exercise tolerance or functional capacity
• Progressive intolerance to GDMT due to hypotension, fatigue or renal dysfunction
• Ventricular arrhythmias or ICD shocks
• Evidence of worsening end-organ dysfunction

“Hospitalization is not a benign event in heart failure,” Dr. Fu says. “Once patients start requiring recurrent admissions, their prognosis changes substantially.”

GDMT Has Transformed Heart Failure Care — But Gaps Remain

Heart failure treatment has evolved dramatically over the past two decades. Current GDMT for heart failure with reduced ejection fraction (HFrEF) now includes:

• Beta blockers
• ACE inhibitors, ARBs or ARNIs
• Mineralocorticoid receptor antagonists
• SGLT2 inhibitors
• Device therapies including CRT and ICDs when indicated

Dr. Fu emphasizes that contemporary therapies have significantly improved survival and quality of life for many patients. “The amount of progress we’ve made in heart failure management over the last 20 to 25 years has been tremendous,” he says.

At the same time, he notes that real-world implementation of GDMT remains inconsistent.

Registry data continue to show substantial gaps in both prescribing evidence-based therapies and titrating medications to target doses.

“We have highly effective therapies available, but many eligible patients still are not receiving them at optimal doses,” Dr. Fu says.

For referring physicians and cardiologists, ongoing reassessment of medication optimization remains critical, particularly after hospitalization or symptomatic decline.

Why Earlier Referral Matters in Advanced Heart Failure

One of the biggest challenges in advanced heart failure care is that patients are frequently referred too late.

By the time many patients are evaluated by advanced heart failure specialists, they may already have developed severe renal dysfunction, frailty, malnutrition or cardiogenic shock that limits treatment options.

“Advanced heart failure referral is not synonymous with transplant,” Dr. Fu says. “The goal is to evaluate the full range of therapies available and determine the right timing for intervention.”

Earlier referral allows multidisciplinary teams to assess candidacy for advanced therapies before irreversible end-organ damage occurs.

Patients who may benefit from advanced heart failure evaluation include those with:

• Persistent NYHA class III or IV symptoms
• Multiple hospitalizations within 6 to 12 months
• Progressive intolerance to GDMT
• Escalating diuretic needs
• Hypotension limiting medication titration
• Worsening renal function
• Refractory arrhythmias
• Inotrope dependence or cardiogenic shock

“Timing matters,” Dr. Fu says. “The earlier we identify worsening heart failure, the more opportunities we have to alter the patient’s trajectory.”

Bridging the Gap Between Medical Therapy and Transplantation

While heart transplantation and durable left ventricular assist devices (LVADs) remain critical therapies for select patients, many individuals fall into an intermediate category — too advanced for standard medical management alone, but not yet transplant or LVAD candidates.

This growing population has created increasing interest in therapies that can bridge the gap between conventional GDMT and advanced surgical intervention.

“There’s a large group of patients who don’t fit neatly into a transplant or LVAD pathway,” Dr. Fu says. “We need additional strategies for patients in that space.”

Emerging therapies aimed at autonomic modulation, hemodynamic optimization and symptom reduction may offer additional options for selected patients with worsening heart failure.

According to Dr. Fu, these therapies are particularly important as heart failure prevalence continues to rise alongside an aging population.

Multidisciplinary Care Is Increasingly Essential

Managing worsening heart failure now requires close coordination across multiple specialties.

At Baptist Health Miami Cardiac & Vascular Institute, advanced heart failure care involves collaboration among:

• General cardiologists
• Advanced heart failure specialists
• Electrophysiologists
• Cardiothoracic surgeons
• Cardiac imaging specialists
• Critical care physicians
• Rehabilitation and palliative care teams

This multidisciplinary model supports more comprehensive management of complex medication regimens, device therapies, transplant candidacy and long-term quality of life.

“Heart failure management has become increasingly complex,” Dr. Fu says. “No single clinician manages these patients alone anymore.”

Practical Considerations for Physicians Managing Heart Failure

Dr. Fu encourages clinicians to focus not only on acute decompensation, but also on longitudinal trends that may suggest worsening disease.

Important considerations include:

• Monitor symptom trajectory over time rather than relying solely on ejection fraction
• Reassess GDMT optimization at every visit
• Recognize recurrent hospitalization as a major prognostic marker
• Refer patients before severe end-organ dysfunction develops
• Consider earlier advanced heart failure evaluation for patients with declining functional status

As heart failure prevalence continues to increase globally, earlier recognition of worsening disease and more proactive referral pathways may help improve outcomes and expand treatment opportunities for patients with progressive heart failure.